For decades, the cholesterol conversation has revolved around a single number: LDL-C, the concentration of cholesterol carried in low-density lipoprotein. It is the figure your physician circles on a lab report, the target of every statin prescription, and the anchor of cardiovascular guidelines worldwide. It is also an incomplete — and at times misleading — measure of the thing that actually drives atherosclerosis.

The Conventional Story

The LDL hypothesis is one of the best-validated ideas in medicine. Lower LDL-C, and you lower cardiovascular events. The statin trials of the 1990s and 2000s established this beyond reasonable doubt, and every major guideline since has used LDL-C as the primary lipid target. The logic is intuitive: cholesterol accumulates in arterial plaque, LDL is the main carrier of cholesterol, so measure the cholesterol in LDL and treat it down.

The trouble is that the hypothesis was always really about particles, not cholesterol mass. And LDL-C measures the wrong one.

What LDL-C Actually Measures

LDL-C is a measure of mass — the total amount of cholesterol cargo inside your LDL particles. It tells you nothing directly about how many particles are carrying that cargo. This matters because LDL particles are heterogeneous: some are large and cholesterol- rich, others small and cholesterol-depleted. Two people can have an identical LDL-C of 100 mg/dL while one carries that cholesterol in a modest number of large particles and the other in a vast number of small, dense ones.

Atherosclerosis is not caused by cholesterol floating freely in the blood. It is caused by lipoprotein particles physically penetrating the arterial wall, becoming trapped, and triggering an inflammatory cascade. The relevant question is therefore not how much cholesterol is present, but how many particles are available to invade the endothelium.

Enter ApoB

Every atherogenic lipoprotein — LDL, but also VLDL, IDL, and lipoprotein(a) — carries exactly one molecule of apolipoprotein B (ApoB) on its surface. One particle, one ApoB. Measuring ApoB therefore gives you a direct count of the total number of atherogenic particles in circulation, regardless of how much or how little cholesterol each one happens to be carrying.

This is a fundamentally better measurement. Where LDL-C estimates cargo, ApoB counts the vehicles. And because it captures VLDL and IDL remnants as well as Lp(a) — not just LDL — it reflects the full atherogenic burden, including the particles that standard lipid panels tend to underweight.

The Discordance Problem

In most people LDL-C and ApoB roughly agree. But in a clinically crucial minority they diverge — a situation called discordance — and when they do, ApoB wins.

The classic discordant patient has the metabolic syndrome phenotype: insulin resistance, elevated triglycerides, low HDL, and a preponderance of small, dense LDL particles. Because those particles are cholesterol-depleted, the LDL-C can read reassuringly normal even as the particle count — and the risk — is high. The lab says "fine." The biology says otherwise.

A patient with an LDL-C of 90 mg/dL and an ApoB of 110 mg/dL is not at low risk. They have a high number of atherogenic particles — each capable of entering the arterial wall. Standard labs missed this entirely.

What the Data Shows

The superiority of ApoB is not a matter of opinion. When ApoB and LDL-C disagree, outcomes track ApoB. The Copenhagen General Population Study, following tens of thousands of individuals, found that ApoB predicted myocardial infarction better than LDL-C and that the excess risk in discordant patients followed the particle count, not the cholesterol mass. Sniderman's meta-analyses comparing LDL-C, non-HDL-C, and ApoB across more than 200,000 patients consistently ranked ApoB as the strongest single predictor of cardiovascular events.

Analyses from statin and nutritional-intervention cohorts point the same way: the residual risk that remains after LDL-C is "treated to target" is explained, in large part, by an ApoB that was never measured. Lowering particle number — not just cholesterol concentration — is what moves outcomes.

Targets

Reasonable ApoB targets are stratified by risk. For someone at moderate cardiovascular risk, an ApoB below 80 mg/dL is a sensible goal. For high-risk individuals — those with established disease, diabetes, or a strong family history — the target tightens to below 60 mg/dL. These thresholds correspond to a meaningfully lower particle burden than the population average, and reaching them is the practical objective of lipid management.

The Lp(a) Addendum

One particle deserves special mention. Lipoprotein(a) — Lp(a) — is an LDL-like particle with an additional protein attached, and its concentration is almost entirely genetically determined. It is atherogenic in its own right, and because each Lp(a) particle also carries an ApoB, a high Lp(a) inflates the total particle count independently of diet or lifestyle.

The combination is what matters: an elevated ApoB and an elevated Lp(a) compounds risk substantially, because you are layering an inherited particle excess on top of an acquired one. Lp(a) should be measured at least once in every adult, since it changes both the risk assessment and the aggressiveness of treatment.

What to Ask Your Physician

If you have only ever had a standard lipid panel, three requests will sharpen your picture considerably:

  • Add ApoB to your next fasting panel — it is inexpensive, widely available, and the single most informative lipid measurement you can obtain.
  • Measure Lp(a) once to establish your genetic baseline; it rarely needs repeating.
  • Track particle number over time, not just cholesterol concentration — and judge any therapy by whether ApoB falls into your target range.

LDL-C is not wrong, exactly. It is simply a proxy — and we now have the direct measurement. When the proxy and the truth disagree, it is worth knowing which one your treatment is chasing.